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Abstract
Background/Aims: This study explored the interest in genomic testing for modest changes in colorectal cancer risk
and preferences for receiving genomic risk communications
among individuals with intermediate disease risk due to a
family history of colorectal cancer. Methods: Surveys were
conducted on 272 men and women at intermediate risk for
colorectal cancer enrolled in a randomized trial comparing a
remote personalized risk communication intervention
(TeleCARE) aimed at promoting colonoscopy to a generic
print control condition. Guided by Leventhal’s Common
Sense Model of Self-Regulation, we examined demographic
and psychosocial factors possibly associated with interest in
SNP testing. Descriptive statistics and logistic regression
models were used to identify factors associated with interest
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in SNP testing and preferences for receiving genomic risk
communications. Results: Three-fourths of participants expressed interest in SNP testing for colorectal cancer risk.
Testing interest did not markedly change across behavior
modifier scenarios. Participants preferred to receive genomic risk communications from a variety of sources: printed materials (69.5%), oncologists (54.8%), primary-care physicians
(58.4%), and the web (58.1%). Overall, persons who were unmarried (p = 0.029), younger (p = 0.003) and with greater
cancer-related fear (p = 0.019) were more likely to express
interest in predictive genomic testing for colorectal cancer
risk. In a stratified analysis, cancer-related fear was associated with the interest in predictive genomic testing in the intervention group (p = 0.017), but not the control group. Conclusions: Individuals with intermediate familial risk for
colorectal cancer are highly interested in genomic testing for
modest increases in disease risk, specifically unmarried persons, younger age groups and those with greater cancer
fear.
© 2014 S. Karger AG, Basel
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Hereditary risk plays a role in approximately 30% of all
colorectal cancer cases [1]. To date, genetic testing for hereditary colon cancer risk has focused on the identification of families with high-risk hereditary colon cancer
syndromes, such as Lynch syndrome and familial adenomatous polyposis. The lifetime colon cancer risks associated with these conditions are significant if there is no
intervention (up to 80% with Lynch syndrome and 100%
with classic familial adenomatous polyposis) [1, 2].
Guidelines for ordering genetic testing to assist in the
identification of these high-risk families, as well as appropriate screening and risk-reduction strategies for affected
individuals, are available from the National Comprehensive Cancer Network, consensus statements and expert
review papers in the literature [1–3].
However, as only 2–5% of colorectal cancer cases are
accounted for by high-risk hereditary conditions, much
of the heritability of colorectal cancer remains unexplained [1, 4]. Family history impacts the colorectal cancer risk in relatives outside of high-risk syndromes depending on the number, degree and age at diagnosis of
affected relatives [4, 5]. While having one or more firstdegree relatives with colorectal cancer is known to increase the risk, recent research shows that combinations
of one affected first-degree relative plus multiple secondor third-degree relatives with colorectal cancer can also
increase colorectal cancer risk by 2–5 fold [5]. Currently,
available screening guidelines for individuals at moderately increased risk for colorectal cancer, referred to here
as intermediate risk, are based on family history [2, 6].
However, some individuals may be unaware of their family history of colon cancer and, thus, their intermediate
cancer risk. Identifying the genetic causes of moderate
increases in familial colorectal cancer risk may allow
more individuals to be aware of their risk through genetic testing, rather than relying solely on family history
analysis, and facilitate further tailoring of screening and
risk-reduction recommendations.
Research surrounding the genetic factors conferring a
moderately increased risk for colorectal cancer has focused on SNPs. SNPs, the most common type of genetic
variation in the human genome, contribute to the multifactorial etiology of chronic diseases, such as gene-environment interactions [7]. Genome-wide association
studies have identified SNPs which occur more or less
frequently in disease versus control populations, and the
odds ratios (ORs) from these studies are being used to
create risk estimates. Generally, SNP testing identifies

small increases in disease risk for a large number of people. Capitalizing on these recent genomic discoveries,
some for-profit companies now offer direct-to-consumer
(DTC) SNP-based testing for common health-related
conditions and traits, including colorectal cancer. Such
companies encourage consumers to manage personal
health risks and make informed health decisions by learning their SNP results.
Controversy surrounds the clinical validity (degree to
which a test accurately predicts disease risk) and utility
(whether test findings benefit disease diagnosis, treatment and management) of SNP testing. Opponents argue
that testing for SNPs is of little clinical value because
known genetic variations only account for a small portion
of the heritability of common diseases as well as the fact
that there are significant environmental contributions to
such diseases [8]. Proponents, however, claim genetic
testing for even modest changes in disease risk may motivate health behavior change beyond typical prevention
efforts [9]. Regardless of limited evidence demonstrating
the benefits of this type of genomic testing, companies
continue to market DTC predictive SNP testing promising health benefits for consumers. A 2011 report from the
Genetics and Public Policy Center listed 8 companies
providing DTC testing specifically for colorectal cancer
and 2 companies providing DTC testing for colorectal
cancer only through a physician. Of the 8 DTC companies, 2 companies offered genetic counseling services
without additional cost, while 3 companies offered genetic counseling services with additional cost [10]. Only
3 of the DTC-testing websites identified the SNPs associated with colorectal cancer risk used in testing; the number of SNPs tested ranged from 4–8 [11, 12]. The risks of
colorectal cancer associated with these SNPs are relatively small and differ by racial/ethnic group [11]. Actual
public interest in DTC genetic testing services is highly
variable with market size estimates ranging from USD
20–730 million [13, 14]. Basic DTC genomic testing is
relatively affordable with personal genome sequencing
available for only USD 99 [11]. The current market fluctuates with new companies emerging, companies dismantling or companies changing their health-related focus within a relatively short time frame [15]. Understanding the public’s interest in and attitudes toward SNP
testing is crucial for the effective and appropriate translation of genomic testing to clinical practice and policy, especially in light of the rapid expansion of DTC testing
[13].
Evidence about consumer interest in and attitudes toward genomic testing is conflicting. Generally, consum-
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ers are interested in tests that cost less and indicate higher increases in disease risk rather than a decrease in risk
[16, 17]. Individuals who have a regular physician, higher
perceived benefits of genetic testing and higher levels of
cancer worry show more interest in SNP testing [16]. Perceived advantages of genetic testing from various study
populations include: motivation for adopting a healthier
lifestyle, sharing genetic risk information with family
members and assisting healthcare providers in monitoring their patients’ health [18, 19]. A recent qualitative
study found that consumers prefer healthcare professionals to provide genomic risk communications rather than
print or computer materials [17]. Such insights can direct
effective integration of SNP testing into clinical practice
for potential behavior change and public health impacts.
Although the clinical validity and utility of genomic
testing for known high-risk hereditary syndromes (e.g.
familial adenomatous polyposis and Lynch syndrome)
are well established [3], most familial colorectal cancer
families have no identifiable genetic etiology. Predictive
testing of SNPs associated with small to moderate increases in colorectal cancer risk is commercially available,
but it is unknown how these tests motivate colorectal cancer screening and other healthy lifestyle behaviors. As an
initial step in the translational pathway, it is important to
understand factors associated with consumer interest in
colorectal cancer susceptibility SNP testing and consumers’ preferences for receiving genomic risk communications. Our study was guided by the Common Sense Model of Self-Regulation of Health and Illness [20]. This model underscores the central roles of cognitions and emotions
in health-related decisions and actions, such as the complex information processing associated with genomic
testing decisions. Genomic test results, specifically SNP
testing, may largely influence an individual’s threat representation about colorectal cancer, beyond family history alone [21]. Little is known about the characteristics
of those who seek SNP testing for colorectal cancer susceptibility and their reasons for seeking testing. In the
current analysis, we examined interest in genomic testing
for colorectal cancer risk among relatives of colorectal
cancer patients (i.e. those at intermediate risk) and factors
associated with interest in testing. We also assessed preferences for receiving genomic risk communications seeing as genomic testing is associated with substantial information demands. Based on the Common Sense Model
of Self-Regulation of Health and Illness, we hypothesized
that in addition to sociodemographic factors, both cognitions and emotions would be associated with interest in
SNP testing for colorectal cancer risk.
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Methods
Study Sample
Our study sample was drawn from male and female participants
enrolled in the Family Colorectal Cancer Risk Awareness and Risk
Education Project (Family CARE). The Family CARE project is an
on-going randomized, controlled trial investigating whether a personalized, remote, theoretically-based risk assessment and telephonic counseling intervention (TeleCARE) is more effective at
motivating colonoscopy screening than a mailed, low-intensity targeted print message delivered to individuals who are considered at
intermediate familial risk for colorectal cancer. The intensive
colorectal cancer risk assessment intervention included a 30–45
min telephone counseling session with a certified genetic counselor, a 4-page tailored visual aid to use during the counseling session
and a tailored follow-up letter. The minimal intervention (control)
consisted of a targeted educational brochure defining colorectal
cancer and discussing familial cancer risk and the role of colonoscopy in preventing colorectal cancer. More detailed descriptions of
the study recruitment, intervention, theoretical and practical rationale, and methods is documented elsewhere [22, 23]. Eligible Family CARE study participants were recruited from 5 state cancer registries – Utah, Idaho, Colorado, New Mexico, and California – the
Huntsman Cancer Center and Intermountain Health Care systems
in Utah. Recruitment occurred in 3 stages by first contacting
colorectal cancer patients in the state cancer registries, then requesting contact information for patients’ family members and finally contacting family members directly. Briefly, eligibility criteria
included: (1) age 30–74; (2) having either one first-degree relative
diagnosed with colorectal cancer before age 60, or one first-degree
relative and an additional second-degree relative diagnosed at any
age; (3) no prior cancer diagnosis other than non-melanoma skin
cancer; (4) no colonoscopy in the past 5 years; (5) awareness of
colorectal cancer family history; (6) mental competence, and (7)
ability to read and speak English fluently. All participants were
overdue for a screening colonoscopy based on their family history
of the disease. Families with known familial adenomatous polyposis or meeting Amsterdam criteria for Lynch syndrome were excluded from the study. Participants considered in the current analysis included only those who completed the 9-month follow-up
questionnaire and answered a series of questions on SNP testing.
Nearly all of the participants were non-Hispanic white; therefore,
the study was restricted to this group (for whom the findings are
generalizable), resulting in a final sample size of 272.
Independent Variables
The Common Sense Model of Self-Regulation contends that a
health threat (in this case, familial colorectal cancer risk) generates
2 parallel processes – the cognitive process and the emotional process [20, 21]. Based on these parallel processes, we selected the
cognitive processes of perceived control, perceived severity, perceived susceptibility, and the emotional processes of cancer worry,
fear, optimism, and anxiety as probable factors associated with interest in predictive SNP testing. We report Cronbach’s alphas as
measures of the multi-item scales’ internal reliability for our study
population below.
Cognitive Factors
Perceived Control. Perceived behavioral control was assessed
with a single-item measure: ‘How much control do you think you
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have over whether you can prevent colorectal cancer?’ Response
options were ‘no control’, ‘some control’ or ‘complete control’
[24].
Perceived Severity. Perceptions about the severity of colorectal
cancer were measured using the following 4 items adapted from
the Risk Behavior Diagnosis scale [25]: ‘I believe that colorectal
cancer is serious’, ‘I believe that colorectal cancer is harmful’, ‘I
believe that colorectal cancer is a significant disease’, and ‘I believe
that colorectal cancer has serious negative consequences’ (Cronbach’s alpha = 0.94). Response options were on a 5-point Likert
scale ranging from ‘strongly disagree’ to ‘strongly agree’.
Perceived Susceptibility. Perceived susceptibility was measured
using the following 4 items adapted from the Risk Behavior Diagnosis scale [25]: ‘I am at risk for getting colorectal cancer’, ‘It is
possible that I will get colorectal cancer’, ‘I am susceptible to getting colorectal cancer, and ‘It is likely I will get colorectal cancer’
(Cronbach’s alpha = 0.83). Response options were on a 5-point
Likert scale ranging from ‘strongly disagree’ to ‘strongly agree’.
Emotional Factors
Trait Anxiety. Trait anxiety was assessed with an 8-item subscale taken from the NEO Personality Inventory [26]. The measure demonstrated acceptable internal consistency (Cronbach’s
alpha = 0.79) in the present sample.
Cancer Worry. We assessed frequency and intensity of cancer
worry with a 3-item measure [27]. Worry frequency was measured
using a single-item that asked participants how often they worried
about developing colorectal cancer in their lifetime. Response options were on a 5-point Likert scale ranging from ‘never’ to ‘all of
the time’. Two-items assessed worry intensity by asking participants: ‘How bothered are you by thinking about getting colorectal
cancer’ and ‘How worried are you about getting colorectal cancer?’
Response options were on a 5-point Likert scale ranging from ‘not
at all’ to ‘extremely’. Worry frequency and worry intensity were
combined to create a composite worry variable (Cronbach’s
alpha = 0.80).
Fear. We measured participants’ fear about developing colorectal cancer using the unpublished 6-item Negative Affect in Risk
scale developed by Hay et al. [28] at Memorial Sloan Kettering
Cancer Center in New York City. The scale included the following
statements: ‘I get frightened when I think I could get colorectal
cancer’, ‘Thinking about getting colorectal cancer makes me
afraid’, ‘I get a bad feeling just thinking about the possibility of getting colorectal cancer’, ‘Thinking about my chances of getting
colorectal cancer makes me uncomfortable’, ‘I dread getting
colorectal cancer’, and ‘I can’t think about getting colorectal cancer
without feeling afraid’. Response options were on a 4-point Likert
scale ranging from ‘strongly disagree’ to ‘strongly agree’. The scale
demonstrated high internal consistency (Cronbach’s alpha = 0.93)
in our sample.
Optimism. Optimism was measured using the following 6 items
adapted from the Life Orientation Test-Revised [29]: ‘In uncertain
times, I usually expect the best’; ‘If something can go wrong for me,
it will’; ‘I’m always optimistic about the future’; ‘I hardly ever expect things to go my way’; ‘I rarely count on good things happening
to me’; and ‘Overall, I expect more good things to happen to me
than bad’ (Cronbach’s alpha = 0.87). Response options were on a
5-point Likert scale ranging from ‘strongly disagree’ to ‘strongly
agree’.
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Additional Variables
Sociodemographics. We assessed age, gender, marital status, income, education, health insurance status, rural/urban residence,
and access to a personal healthcare provider. Rural/urban residence was based on Rural-Urban Commuting Area Codes at the
census tract level [30]. Race/ethnicity was not included in the analysis because almost all participants were non-Hispanic white, thus,
limiting statistical power to draw meaningful conclusions regarding racial/ethnic differences in genomic testing interest. Finally, we
included whether participants were in the intervention or control
arm of the Family CARE study. The study arm received a multifaceted genomic risk and behavior change intervention over the
telephone with a certified genetic counselor (TeleCARE) and
mailed tailored materials while the control arm only received a
brochure on familial colorectal cancer risk and colonoscopy
screening.
Risk Behavior Profile. Three modifiable risk factors – physical
activity, BMI and smoking status – were used to create a studyspecific risk behavior index. Participants were considered compliant with the 2008 Physical Activity Guidelines if they reported at
least 150 min a week of moderate-intensity exercise, or 75 min a
week of vigorous-intensity aerobic physical activity, or an equivalent combination of moderate and vigorous intensity aerobic activity [31]. Those meeting these guidelines received a 1 and participants not meeting these guidelines received a 0. We used the standard BMI weight categories as suggested by the Centers for Disease
Control and Prevention [32]. Those in the underweight and average weight categories received a 1 while participants in the overweight and obese categories received a 0. Participants not currently smoking received a 1 and current smokers received a 0. Scores
ranged from 0 (all risk behaviors) and 3 (no risk behaviors). Similar
risk behavior indices were utilized in previous studies [33, 34].
Outcome Variables
Interest in Genomic Testing. Prior to responding to a series of
questions on interest in SNP testing and preferences for receiving
genomic risk communications, participants were briefly introduced to SNPs and genetic testing. The information covered how
genes influence health, genetic testing and disease risk, SNPs, genetic testing processes, and the predictive power of SNPs for
colorectal cancer risk. To determine overall interest in genomic
testing for modest changes in colorectal cancer risk, we first asked
participants ‘If SNP testing could tell you that you may have a
slightly increased risk of developing colorectal cancer, how likely
is it that you would want a SNP test?’ with 4 response options – ‘I
would definitely not have the test,’ ‘I would probably not have the
test,’ ‘I would probably have the test,’ and ‘I would definitely have
the test.’ Due to small numbers in the first level, responses were
dichotomized to those not interested in SNP testing and those interested in SNP testing.
We also examined if interest in SNP testing varied according to
the potential for colorectal cancer risk reduction through behavior
change – regular colorectal cancer screenings, taking medications,
and diet or exercise. Finally, we assessed participants’ preferences
regarding modes of genomic risk communications including print
or written sources, web-based sources, computer kiosk touch
screen, in person with a nurse, in person with a primary care physician, in person with an oncologist and in person with a genetic
counselor. The survey briefly explained the function of genetic
counselors.
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Table 1. Characteristics of Family CARE participants by completion status of the 9-month follow-up survey that assessed interest in
predictive SNP testing for colorectal cancer risk

Gender
Male
Female
Age, years
<45
45 – 60
≥60
Married
Yes
No
Education
High school or less
Some college
College graduate
Income, USD
<30,000
30,000 – 49,999
50,000 – 69,999
≥70,000
Refused
Health insurance
Yes
No
Personal healthcare provider
Yes
No
Close relatives with colorectal cancer diagnosis
1
>1
Rural/urban status
Urban
Rural
Cancer worry score
Low
Moderate
High
Perceived severity
High
Low

Completed, n (%)
(n = 272)

Not completed, n (%) χ2
(n = 182)

97 (35.7)
175 (64.3)

97 (53.3)
85 (46.7)

84 (30.9)
131 (48.2)
57 (21.0)

61 (33.5)
96 (52.8)
25 (13.7)

213 (78.3)
59 (21.7)

124 (68.1)
58 (31.9)

44 (16.2)
116 (42.6)
112 (41.2)

43 (23.6)
79 (43.4)
60 (33.0)

46 (16.9)
50 (18.4)
50 (18.4)
97 (35.7)
29 (10.7)

32 (17.7)
39 (21.6)
20 (11.1)
72 (39.8)
17 (9.4)

227 (83.5)
45 (16.5)

149 (82.3)
32 (17.7)

180 (66.2)
92 (33.8)

119 (65.4)
63 (34.6)

200 (73.5)
71 (26.1)

141 (77.5)
41 (22.5)

211 (77.6)
61 (22.4)

141 (77.5)
41 (22.5)

66 (24.3)
81 (29.8)
125 (46.0)

36 (23.5)
51 (33.3)
66 (43.1)

216 (79.4)
56 (20.6)

130 (71.4)
52 (28.6)

Statistical Analysis
Descriptive statistics were used to characterize sociodemographic, clinical and psychological variables of the study population, delineate interest in SNP testing generally and according to
behavioral modifiers specifically as well as preferences for receiving genomic risk communications. Differences in the characteristics between survey respondents and nonrespondents were assessed using χ2 tests. Unadjusted ORs and 95% confidence intervals (CIs) were used to identify each variable’s association with
interest in SNP testing in the overall study population and by intervention subgroup. Multivariable logistic regression models
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p value

13.86

<0.001

3.84

0.147

5.90

0.015

5.11

0.078

6.54

0.257

0.10

0.753

0.30

0.862

0.79

0.375

0.00

0.980

0.59

0.743

3.83

0.050

were used to identify factors that were independently associated
with interest in SNP testing. Variables with crude statistical significance (p < 0.20) were entered into the regression model and
backward elimination procedures were used to determine which
variables remained in the model (p < 0.10) [27]. We used generalized linear mixed models (Proc GLIMMIX) to account for familial clustering in the study design, but no design effect was observed. Further, in a sensitivity analysis using logistic regression
models (Proc Logistic) without familial clustering, the OR estimates were within 0.01 points of one another. However, all study
results presented here were calculated using generalized linear
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%
100

Not at all/a little
Somewhat
Very much

90

90.4%

80
70
60

54.6%

50.9%

50
40.8%

40
30

30.5%

41.9%

45.3%

41.6%

33.1%

32.6%

34.3%

28.7%
25.0%

24.1%

30.7%

30.8%

24.1%
18.3%

20
12.8%
8.8%

10
0

0.8%

Print or
written
information

Web-based
information

In person
Computer
with a nurse
kiosks touch
screen in a clinic

In person
with a primary
care physician

In person
with an
oncologist

In person
with a genetic
counselor

Fig. 1. Preferences for receiving genomic risk communication.

mixed models. Independent variables with a non-normal distribution were dichotomized or grouped into tertiles accordingly.
Only participants with valid scale scores, as defined by validation
studies for each measure, were included in the analyses. All analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, N.C.,
USA, 2001).

Participants that completed the 9-month assessment
differed from participants that did not complete the
9-month survey by gender χ2 [(1, n = 454) = 13.86, p <
0.01] and marital status χ2 [(1, n = 454) = 5.90, p = 0.015)]
(table 1). We found no significant differences in age
group, education level, insurance status, rural/urban residence, number of relatives with colorectal cancer, cancer
fear, cancer worry, and perceived susceptibility between
those with completed 9-month assessments and those
without.
Characteristics of the study population are presented
in table 2. In the overall study population, most participants were married (78%), attended at least some college

(84%), had health insurance coverage (83%), reported
access to a personal healthcare provider (66%), lived in
urban areas (78%), and all had at least one first-degree
relative with colorectal cancer. Approximately 64% of
participants were female and, on average, participants
were 51.2 years of age (SD = 9.63 years; range 34–74
years). Overall, 74% of participants indicated at least
some interest in predictive SNP testing for colorectal
cancer. Specifically, 4% of participants said they would
definitely not have SNP testing, 22% said they would
probably not have testing, 47% said they would probably
have testing, and 27% said they would definitely have
testing. Interest in SNP testing did not markedly change
between behavior modification scenarios. More participants (77%) expressed interest in genomic testing that
would indicate whether or not their risk of colorectal
cancer could be lowered by diet and exercise than having
regular colonoscopies or taking medication (data not
shown). The most commonly preferred sources of genomic risk information were print sources (69.5%), oncologists (54.8%), primary-care physicians (58.4%), and
web-based sources (58.1%) (fig. 1).

Interest in Genomic Testing for
Colorectal Cancer Risk

Public Health Genomics 2014;17:48–60
DOI: 10.1159/000356567

Results

53

54

Public Health Genomics 2014;17:48–60
DOI: 10.1159/000356567

Anderson et al.

Gender
Male
Female
Age, years
<45
45 – 60
>60
Married
Yes
No
Education
High school or less
Some college
College graduate
Income, USD
<30,000
30,000 – 49,999
50,000 – 69,999
≥70,000
Health insurance
Yes
No
Personal healthcare provider
Yes
No
Relatives with colorectal cancer diagnosis
1
>1
Rural/urban status
Urban
Rural
Cancer worry score
Low
Moderate
High
Perceived severity
High
Low
Perceived control
No control
Some/complete control
3.54 (1.10 – 11.37)
3.34 (1.18 – 9.45)
1.00 (Reference)
1.00 (Reference)
1.25 (0.46 – 3.36)
1.38 (0.42 – 4.57)
1.10 (0.45 – 2.71)
1.00 (Reference)
0.47 (0.15 – 1.52)
1.07 (0.31 – 3.73)
0.98 (0.30 – 3.24)
1.00 (Reference)
1.00 (Reference)
0.60 (0.19 – 1.86)
1.00 (Reference)
0.94 (0.39 – 2.29)
1.00 (Reference)
1.21 (0.48 – 3.05)
1.00 (Reference)
0.93 (0.37 – 2.39)
1.00 (Reference)
0.96 (0.37 – 2.49)
2.95 (0.98 – 8.89)
1.00 (Reference)
0.38 (0.16 – 0.88)
0.32 (0.05 – 2.21)
1.00 (Reference)

94 (77.7)
27 (22.3)
21 (17.4)
53 (43.8)
47 (38.8)
21 (17.4)
21 (17.4)
23 (19.0)
42 (34.7)
105 (86.8)
16 (13.2)
84 (69.4)
37 (30.6)
88 (72.7)
33 (27.3)
92 (76.0)
29 (24.0)
43 (35.5)
40 (33.1)
38 (31.4)
76 (63.3)
44 (36.7)
5 (4.1)
116 (95.9)

1.48 (0.58 – 3.80)
1.00 (Reference)

OR (95% CI)

37 (30.6)
59 (48.8)
25 (20.7)

34 (28.1)
87 (71.9)

n (%)

a

TeleCARE (n = 121)

0.231

0.026

0.093

0.881

0.668

0.888

0.356

0.673

0.856

0.647

0.051

0.395

p value

12 (8.1)
137 (92.0)

84 (56.0)
66 (44.0)

50 (33.3)
44 (29.3)
56 (37.3)

119 (78.8)
32 (21.2)

112 (74.7)
38 (25.3)

96 (63.6)
55 (36.4)

122 (80.8)
29 (19.2)

25 (16.6)
29 (19.2)
27 (17.9)
55 (36.4)

23 (15.2)
63 (41.7)
65 (43.1)

119 (78.8)
32 (21.2)

47 (31.1)
72 (47.7)
32 (21.2)

63 (41.7)
88 (58.3)

n (%)

a

1.29 (0.25 – 6.61)
1.00 (Reference)

1.00 (Reference)
1.04 (0.45 – 2.42)

1.00 (Reference)
1.17 (0.43 – 3.17)
2.45 (0.85 – 7.10)

1.00 (Reference)
1.14 (0.41 – 3.21)

1.00 (Reference)
0.73 (0.29 – 1.83)

1.00 (Reference)
0.83 (0.35 – 1.95)

1.00 (Reference)
1.27 (0.43 – 3.81)

1.37 (0.37 – 5.11)
1.22 (0.36 – 4.16)
0.91 (0.28 – 2.96)
1.00 (Reference)

0.76 (0.22 – 2.65)
0.71 (0.28 – 1.78)
1.00 (Reference)

1.00 (Reference)
2.93 (0.80 – 10.82)

4.66 (1.35 – 16.06)
2.19 (0.82 – 5.87)
1.00 (Reference)

0.32 (0.13 – 0.76)
1.00 (Reference)

OR (95% CI)

Control (n = 151)

0.751

0.914

0.224

0.797

0.488

0.662

0.659

0.938

0.742

0.104

0.049

0.011

p value

17 (6.3)
253 (93.7)

160 (59.3)
110 (40.7)

93 (34.3)
84 (31.0)
94 (34.7)

211 (77.6)
61 (22.4)

200 (73.8)
71 (26.2)

180 (66.2)
92 (33.8)

227 (83.5)
45 (16.5)

46 (16.9)
50 (18.4)
50 (18.4)
97 (35.7)

44 (16.2)
116 (42.7)
112 (41.2)

213 (78.3)
59 (21.7)

84 (30.9)
131 (48.2)
57 (21.0)

97 (35.7)
175 (64.3)

n (%)a

0.84 (0.28 – 2.52)
1.00 (Reference)

1.00 (Reference)
0.66 (0.38 – 1.17)

1.00 (Reference)
1.02 (0.53 – 1.97)
2.68 (1.29 – 5.60)

1.00 (Reference)
0.99 (0.51 – 1.92)

1.00 (Reference)
0.93 (0.50 – 1.75)

1.00 (Reference)
0.93 (0.52 – 1.68)

1.00 (Reference)
0.96 (0.46 – 2.02)

0.75 (0.34 – 1.68)
1.14 (0.49 – 2.62)
0.94 (0.42 – 2.09)
1.00 (Reference)

1.00 (0.44 – 2.29)
0.88 (0.48 – 1.63)
1.00 (Reference)

1.00 (Reference)
1.71 (0.82 – 3.57)

3.86 (1.74 – 8.56)
2.63 (1.33 – 5.21)
1.00 (Reference)

0.74 (0.418 – 1.32)
1.00 (Reference)

OR (95% CI)

Overall (n = 272)

Table 2. Crude ORs and 95% CIs for interest in predictive SNP testing for colorectal cancer risk for the overall study population and by intervention subgroup

0.745

0.153

0.018

0.969

0.822

0.807

0.916

0.901

0.905

0.151

0.003

0.307

p value

0.850
0.008
0.765
0.214
1.01 (0.94 – 1.08)
1.69 (1.15 – 2.48)
1.01 (0.95 – 1.07)
1.07 (0.96 – 1.20)
16.3 ± 3.8*
2.3 ± 0.8*
16.9 ± 5.0*
14.5 ± 2.7*
0.95 (0.85 – 1.06)
2.08 (1.16 – 3.73)
1.03 (0.95 – 1.11)
1.11 (0.92 – 1.33)
15.9 ± 3.9*
2.2 ± 0.8*
16.9 ± 5.2*
14.7 ± 2.3*

1.06 (0.95 – 1.18)
1.38 (0.79 – 2.39)
0.98 (0.91 – 1.07)
1.07 (0.91 – 1.25)

0.265
0.250
0.694
0.398

16.1 ± 3.9*
2.3 ± 0.8*
16.9 ± 5.1*
14.6 ± 2.5*

1.97 (1.12 – 3.47)
1.00 (Reference)
151 (55.5)
121 (44.5)

0.020

0.822
1.22 (0.55 – 2.71)
1.23 (0.61 – 2.49)
1.00 (Reference)
69 (26.9)
120 (46.7)
68 (26.5)
0.289
1.84 (0.58 – 5.81)
2.24 (0.79 – 6.34)
1.00 (Reference)
40 (28.0)
67 (46.9)
36 (25.2)

Percentages may not total 100% due to rounding. * Mean ± SD.
a

Risk behavior score
1
2
3
Intervention group
Control
Intervention
Continuous variables
Optimism
Cancer fear
Anxiety
Perceived susceptibility

0.342
0.017
0.461
0.261

0.761
0.77 (0.23 – 2.57)
0.69 (0.24 – 1.98)
1.00 (Reference)

n (%)

p value
OR (95% CI)
n (%)

29 (25.4)
53 (46.5)
32 (28.1)

p value
OR (95% CI)
n (%)a
OR (95% CI)

p value

Overall (n = 272)
Control (n = 151)

a
a

TeleCARE (n = 121)

Table 2 (continued)

Interest in Genomic Testing for
Colorectal Cancer Risk

Table 2 presents unadjusted ORs, 95% CIs and p values for each independent variable in the overall study
population and by intervention subgroup. Age, marital
status, worry, perceived severity, cancer fear, and intervention group met the criteria (p < 0.20) for entry into
the logistic model for the overall study population. For
the TeleCARE group, age, worry, perceived severity, and
cancer fear were used in the logistic model. For the control group, gender, age and marital status were included
in the model.
The final adjusted logistic models included variables
(p < 0.10) shown in table 3. Overall, unmarried individuals expressed greater interest in SNP testing than married
participants (OR = 2.49, 95% CI = 1.10–5.61, p = 0.029).
Participants less than 45 years indicated more interest in
testing than those over 65 years (OR = 4.26, 95% CI =
1.81–10.01, p = 0.003). Those in the control group were
more interested in genomic testing than those in the intervention group (OR = 2.05, 95% CI = 1.12–3.74, p =
0.021). Participants reporting higher levels of cancer fear
were more likely to indicate interest in SNP testing than
those with lower fear levels (OR = 1.61, 95% CI = 1.09–
2.43, p = 0.019). In a stratified analysis, the models differed by intervention subgroups. For the control group,
age and marital status were associated with interest in
SNP testing and males were less likely to express interest
in SNP testing compared to females (OR = 0.30, 95%
CI = 0.12–0.74, p = 0.011). Only cancer fear was significantly associated with interest in SNP testing for the intervention group (OR = 2.08, 95% CI = 1.16–3.73, p =
0.017). To assess the combined effect of risk perceptions
and select emotions, we tested for interactions between
perceived risk and worry as well as perceived risk and
fear. However, we found no significant interactions.

Discussion

To our knowledge, this is the first study to measure
interest in predictive SNP testing for modest changes in
colorectal cancer risk and preferences for receiving genomic risk information among at-risk relatives of colorectal cancer patients. Overall interest in SNP testing was
high in our sample, with approximately three-fourths of
the study population expressing at least some interest in
testing, despite only small to modest increases in disease
risk. Participants in the Family CARE project were made
aware of their increased familial risk for colorectal cancer,
perhaps causing greater interest in genetic testing than in
the general population. However, a small study of average
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Table 3. Adjusted logistic regression models for the overall study

population and by intervention subgroup for interest in predictive
SNP testing for colorectal cancer risk

Overall
Married
Yes
No
Age, years
<45
45 – 60
>60
Intervention group
Control
Intervention
Cancer fear
Control
Married
Yes
No
Age, years
<45
45 – 60
>60
Gender
Male
Female
Intervention
Cancer fear

Adjusted OR*

95% CI

1.00
2.49

Reference
1.10 – 5.61

4.26
2.83
1.00

1.81 – 10.01
1.35 – 5.92
Reference

2.05
1.00
1.61

1.12 – 3.74
Reference
1.09 – 2.43

1.00
4.09

Reference
1.01 – 16.55

5.54
2.25
1.00

1.49 – 20.65
0.78 – 6.53
Reference

0.30
1.00

0.12 – 0.74
Reference

2.08

1.16 – 3.73

p value*
0.029
0.003

0.021
0.019
0.048
0.041

0.011

0.017

* Adjusted for all variables included in the final model for each
group.

risk primary care patients also found that 75% of participants expressed interest in SNP testing for increased
colorectal cancer risk [17].
Interest in SNP testing did not appreciably change
across behavior modification scenarios, with interest remaining close to 75%. These findings are noteworthy in
light of the recent debate surrounding genomic testing
and the potential for health behavior change [35]. Our
study’s participants did not express more interest in SNP
testing with behavior risk modifiers, suggesting that genomic testing results alone may not motivate health behavior change. A population-based study comparing relatives of colorectal cancer patients to controls found that
25% of participants with a hypothetical positive predictive genomic test result would exercise ‘a lot more’ while
30% claimed they would make significant dietary changes. There was no significant difference between relatives
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and controls [9]. However, intentions to change behavior
based on a hypothetical test result do not necessarily reflect actual behavior modifications influenced by genomic testing. In another study, women at increased risk for
hereditary breast cancer reported statistically less interest
in SNP testing with behavior-risk modifiers, like daily vitamins or exercise and healthy diets, than testing for genetic factors that conferred risk for breast cancer independent of lifestyle factors [16]. Similarly, there was no
significant difference in dietary fat intake, exercise and
screening behaviors from baseline to follow-up in adults
who received DTC genome-wide profiling [36]. Current
evidence suggests that although genetic susceptibility information may function as a cue to action or catalyst for
behavior modification, it may not be enough to motivate
sustained health behavior change [37, 38]. Genomic test
results that confer a modest increase in cancer risk may
result in health behavior change among highly motivated
individuals. But, most consumers of genomic testing likely need action-oriented health counseling or other evidence-based health education strategies to enact behavior
change following personalized genomic testing [39]. It is
not clear, however, if genomic testing adds value to evidence-based behavioral interventions. More research in
this area is needed to establish the clinical utility of SNP
and other genomic testing for common risk variants.
Age, marital status, intervention group, cancer worry,
perceived cancer risk, and cancer fear achieved crude statistical significance in the bivariate analysis. Age, marital
status, intervention group, and cancer-related fear were
independently associated with interest in genomic testing
in the overall study population. Cancer-related fear was
associated with interest in SNP testing in the intervention
group, but not in the control group. The intervention in
this study was designed to raise cancer-related fear while
also providing participants with efficacy tools to manage
this fear. As such, some of the intervention participants
in this study may have residual fear that influences protective motivation processes, and thus, the desire for SNP
testing. Fear has been shown to motivate behavior, leading individuals to seek ways of removing or coping with
the health threat or danger [40]. In one study, genetic
counseling before and after testing for non-polyposis
colorectal cancer relieved cancer fear in participants that
tested either mutation positive or mutation negative after
1 year of follow-up [41]. In the future, it may be important
to determine if and how cancer fear changes with receipt
of SNP genomic test results that confer modest to moderate cancer risk over time and behavior modification scenarios.
Anderson et al.

Prior research found cancer worry to be positively associated with interest in predictive SNP testing for modest changes in breast cancer risk [16, 42]. However, in our
study cancer-related fear was the only emotional factor
independently associated with interest in testing, consistent with the Common Sense Model of Self Regulation.
Cancer worry was associated with interest in SNP testing
in the crude analysis, but did not remain significant in the
multivariable models, perhaps because cancer worry was
moderately correlated with fear (data not shown). We
collapsed cancer worry into 3 categories – low, moderate
and high – because of small numbers, preventing a more
granulated analysis of cancer worry. Constructs included
in the cognitive process (i.e. perceived risk, perceived severity and perceived susceptibility) were not independently associated with interest in testing, suggesting that
emotions may be more important factors than cognitions
in this context.
Age was the most powerful factor associated with interest in predictive SNP testing for the control group and
the overall study population, with the youngest age group
expressing the greatest interest. Interest in testing decreased with increasing age group. Research shows that
younger age groups demonstrate higher health and genetic literacy and are more receptive to emerging technologies than older populations [32]. With higher health
and genetic literacy, younger participants may more fully
understand the genomic testing information provided in
the 9-month follow-up questionnaire which may lead to
greater interest in testing. A prior study found that participants who were confident in their ability to understand genomic information were more likely to express
interest in SNP testing for multiple common health conditions [33]. Also, younger age groups may find genetic
testing more advantageous, possibly because they have
more years of life left to engage in health behavior change
and benefit from knowing personal genomic cancer risk.
For example, a survey on public interest in personal genomic testing found that younger age groups were more
likely to support genomic testing to learn more about
oneself [18]. Age was not associated with testing interest
in the intervention group. But, the family risk information and behavior change counseling session with the intervention group may have mitigated differences in levels
of genomic understanding across age groups, at least to
some degree.
Unmarried individuals were significantly more interested in genomic testing than married participants in the
total study population and in the control group. This was
unexpected, as marital status was either not associated

with genomic testing interest in prior studies [16, 17] or
married individuals were more interested in testing than
unmarried participants [43, 44]. Participants who responded to the 9-month survey were more likely to be
married compared to nonrespondents, possibly introducing response bias. We may be underestimating interest in SNP testing for unmarried individuals. Members of
an unmarried couple, separated, divorced, widowed, and
never married participants were all considered ‘unmarried’ because of small numbers, precluding a more granular analysis. We were unable to determine if participants
in these groups were more or less likely than married individuals to express interest in genomic testing. Sharing
genetic risk information with family members, specifically children, is frequently cited as an advantage of genomic testing [17–19]. As such, parental status may moderate the relationship between marital status and interest
in genomic testing. Unfortunately, we did not measure
whether or not participants have children in our study,
but future research should consider parental status as a
possible factor associated with interest in genomic testing.
Those in the control arm of the Family CARE study,
receiving only an educational brochure targeted at their
familial risk group, expressed significantly more interest
in predictive SNP testing for colorectal cancer risk than
those randomized to the higher intensity TeleCARE intervention arm of the study. During the genetic counseling session, participants in the TeleCARE arm of the
study received extensive information on how family history contributes to colorectal cancer risk, but did not necessarily learn about genomic testing. Families with known
familial adenomatous polyposis or meeting Amsterdam
criteria for Lynch syndrome were excluded from the
study; as such, most participants did not receive any recommendation for genomic testing from the genetic counselors. Some participants did inquire about genetic testing for colorectal cancer on their own; however, most did
not have a family history that warranted genetic testing
for any high-risk cancer syndromes. Many TeleCARE
participants likely felt they already understood their
colorectal cancer risk based on the family history risk assessment they received as part of the Family CARE study
and consequently, would not benefit from personal genomic testing. The control group, on the other hand, may
have felt less informed about their familial and genetic
risk of colorectal cancer and, therefore, be more interested in pursuing additional information about their personal genomic risk. Differences in the intervention content and dose between the 2 arms may explain why the
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control group expressed greater interest in SNP testing
than the intervention group.
Participants most frequently cited print sources and
physicians as their preferred methods for receiving genomic risk communications. During the Family CARE
study, all participants received information on familial
colorectal cancer risk via mailed educational brochures.
TeleCARE participants also received tailored mailed
print materials and one-on-one telephone education and
counseling by cancer risk specialists. In this case, participants’ familiarity with print materials to communicate
cancer risk may contribute to the high proportion of respondents endorsing print/written sources. Printed materials allow individuals to read and digest information at
their own pace, but lack interaction with a physician or
genetic counselor. In similar studies, people also preferred that genetic risk information be delivered in person by a healthcare provider, such as a primary care physician or oncologist [17, 45]. However, available evidence
suggests that most primary care providers lack both time
and expertise to effectively communicate genomic risk
information with patients. A survey of primary care providers found that only 39% of physicians were aware of
DTC genomic testing and 85% of physicians felt unprepared to discuss genomic testing with patients [46]. Early
adopters of personalized genomics not only intended to
share their testing results with a physician, but also expected their physician to tailor their healthcare needs
based on personal genomic information [47]. There are
currently no clinical guidelines or evidence to support
health interventions following SNP testing (e.g. screening
frequency, diet/lifestyle interventions) possibly making
clinicians even more hesitant to interpret SNP results for
patients. Without adequate time and sufficient knowledge, primary care physicians cannot meet such demands.
It is important to note that these studies only evaluated
intentions to consult primary care providers, not actions.
But, a recent study reported that 27% of adults who received DTC genomic testing shared their results with a
healthcare provider; those sharing their testing results
with a provider were more health conscious and expressed fewer genomic-related privacy concerns [39].
Predictive SNP testing for common health-related conditions cannot be effectively translated into clinical practice
without both patients and providers understanding the
implications of genomic testing.
Limitations to this study deserve discussion. First, we
did not include the cost of predictive SNP testing in the
survey. Graves et al. [16] found that interest in SNP testing for modest changes in breast cancer risk increased as
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test-associated costs decreased. Although we did not
measure cost, it is still interesting to note that three-quarters of participants expressed interest in predictive SNP
testing. Second, participants were only provided with a
brief overview of genetics, disease risk and SNPs. Such a
short introduction may not be enough information for
participants to determine whether or not they are interested in SNP testing, especially those with low levels of
health/genetic literacy. Future studies should assess interest and testing uptake after accounting for previous genetic knowledge and genetic literacy and following a
more detailed discussion of the issues surrounding predictive SNP testing, like controversial clinical validity and
utility. We only assessed whether or not participants were
interested in SNP testing, not reasons for interest or actual uptake of genomic testing. Third, we recognize that
our findings may not be generalizable to the whole population. Not all Family CARE participants completed the
9-month follow-up questionnaire resulting in possible response bias. However, respondents only differed from
nonrespondents in gender and marital status. Our study
population was rather homogenous and limited to nonHispanic whites, thereby limiting the generalizability of
our findings. All study participants were participating in
an intervention trial and were nonadherent to colorectal
cancer screening guidelines. We might see different levels
of interest in a different study sample. Our results may
not reflect the attitudes of the general population because
those who participate in research studies are different
from those in the general population. Finally, the small
sample size in some strata may have limited our statistical
power to detect small differences. Results should be interpreted in context of these limitations.
Our study is a first step toward understanding interest
in genomic testing for modest increases in disease risk
and preferences for receiving genomic risk communications. Interest in predictive SNP testing for colorectal
cancer was high among relatives of colorectal cancer cases. Participants preferred to receive genomic risk communications from a variety of sources including print,
healthcare providers – such as primary care physicians –
and the web. Primary care physicians, however, may not
be prepared to interpret genomic testing results or provide genomic risk communications [48, 49]. As such, educational interventions are needed for both patients and
primary care providers to facilitate effective and appropriate translation of predictive genomic testing into clinical practice, especially when considering the expansion
of DTC genetic testing. The DTC genetic testing market
is currently unregulated with little oversight to ensure
Anderson et al.

quality testing or full disclosure of the limitations of these
tests, including their predictive value. Public interest in
SNP testing may change, if these limitations are explicitly
stated. If clinic validity and utility is established for certain SNP tests, these tests could conceivably become a
standard of care. Behavioral intervention research can
help guide future policy and clinical practice guidelines,
like developing provisions for genetic education and
counseling. Future research should also address dissemination of genomic risk communications to underserved
populations who are less likely to seek genetic testing or
to understand genetic risk results. Although we studied
predictive SNP testing for colorectal cancer risk, the present findings apply to other genomic tests for modest increases in disease risk.
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